Notice of Data Security Incident.
The National Institutes of Health (NIH) recommends neutralizing monoclonal antibody therapy for patients diagnosed with mild to moderate COVID-19 infection who do not currently require hospitalization but are at high risk for progression to severe infection and hospitalization or death.
There are currently 2 monoclonal antibody therapies authorized for emergency use by the FDA, REGEN-COV (Casirivimab plus Imdevimab) and Sotrovumab. Treatment should be started as soon as possible after the patient receives a positive SARS-CoV-2 test and within 10 days of symptom onset. As of July 30, 2021, the FDA has expanded the emergency use authorization of REGEN-COV for post-exposure prophylaxis in certain people exposed to a SARS-CoV-2 infected individual, or who are high risk of exposure to an infected individual in an institutional setting.
Monoclonal Antibody therapies are given as an intravenous infusion or subcutaneous injection at a dedicated infusion clinic only. You must have a referral and order from a provider in order to receive this medication. CHI Health has infusion centers available at multiple sites across Nebraska, Western Iowa, and Bismarck, ND.
If you are curious if you qualify for treatment or post-exposure prophylaxis, consult with your provider first. If you do not have a primary care provider, you may chat with Virtual Quick Care.
